EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›GCO

GCO

GENESCO INC

Next earnings Aug 26, 2026 · consensus $-1.25 EPS, $534M rev

Last earnings +5.5% on 2026-05-29

Sell
$36.18
▲ +4.15%
$36.18▲ +72.29%
over 1Y
L $19.69EODHDH $42.72
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.1%
1W+1.1%
1M-2.7%
3M+29.4%
YTD+46.3%
1Y+72.3%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Sell
Quality
B-
Valuation
Undervalued
Filings
Flagged
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy

Thin net margin (0.5%).

Revenue (FY2026) $2.44B · FY2026

The read

It screens cheap (~23% below fair value), but the weak fundamentals are why — more potential value trap than bargain.

GENESCO INC shows $2.44B in FY2026 revenue (+4.8% YoY), a 0.5% net margin, and 2.3% ROE.

Financials · annual, by fiscal year

Line itemFY22FY23FY24FY25FY26
Revenue$2.42B$2.38B$2.32B$2.33B$2.44B
Gross profit$1.18B$1.14B$1.10B$1.10B$1.13B
Operating income$156M$93.2M-$13.5M$13.9M$17.3M
Net income$115M$71.9M-$16.8M-$18.9M$13.3M
Diluted EPS$7.92$5.66-$1.50-$1.74$1.25
Net margin4.7%3.0%-0.7%-0.8%0.5%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$291M
EV / EBITDA4.1
EV / Sales0.1
EV / FCF3.5
P / FCF4.7
PEG (trailing)0.17
Earnings yield3.4%
FCF yield21.3%

Quality & risk

ROIC (est.)2.4%
Free cash flow$83.7M
Total debt$3.38M
Net cash$102M
Altman Z-Score2.55 grey
Piotroski F-Score7/9

Capital returns

Buyback yield3.2%
Dividend yield (est.)—
Shareholder yield3.2%
Shares Δ YoY-1.6%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Red flag in recent filings — restated periodic report (2026-06-01). Worth a closer look.
  1. 10-Q Quarterly report2026-06-11
  2. 10-K/A Restated periodic report2026-06-01
  3. 8-K Earnings results2026-05-29
  4. 8-K Officer / director change2026-05-05
  5. 8-K Officer / director change2026-04-08
  6. 8-K Officer / director change2026-03-27
  7. 10-K Annual report2026-03-25
  8. 8-K Earnings results2026-03-06
  9. 8-K Officer / director change2026-01-29

Recent filings

all on EDGAR ↗
DEFC14AFiling2026-06-18open ↗DEFA14AFiling2026-06-16open ↗PRRN14AFiling2026-06-16open ↗ARSPeriod ending 2026-01-312026-06-15open ↗DEFC14AFiling2026-06-15open ↗PRER14AFiling2026-06-11open ↗10-QPeriod ending 2026-05-022026-06-11open ↗SCHEDULE 13D/AFiling2026-06-10open ↗PREC14AFiling2026-06-08open ↗PREC14AFiling2026-06-03open ↗10-K/APeriod ending 2026-01-312026-06-01open ↗8-KPeriod ending 2026-05-292026-05-29open ↗

Quality score

B-
ValueGrowthProfitHealthMom.
ValueB+
GrowthB+
ProfitabilityD
Financial healthB+
Momentum—
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
  • ✗P/E below 25

Fair value est.

$44.35

Undervalued +23% vs price

cheapfair valueexpensive

Modified Graham: EPS $1.25 × (8.5 + 1.5 × 22.0% growth) × 0.85 quality = 35.5× multiple. An estimate, not a price target.

Revenue
$2.44B
+4.8% YoY
Net margin
0.5%
ROE
2.3%
P/E
28.9

SEC fundamentals · FY 2026

'22'23'24'25'26

■ revenue · ■ net income, by fiscal year

Revenue$2.44B+4.8%
Net income$13.3M+170.2%
Gross profit$1.13B+2.7%
Operating income$17.3M+24.3%
Diluted EPS$1.25+171.8%
Cash & equivalents$105M+210.0%
Total assets$1.39B+4.3%
Total liabilities$826M+4.7%
Stockholders' equity$567M+3.7%
Gross: 46.3%Op.: 0.7%L/E: 1.46x

Frequently asked

Is GENESCO INC (GCO) a buy?
GCO currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Thin net margin (0.5%).
What is GCO's fair value?
A Modified-Graham model based on GCO's SEC fundamentals estimates a fair value of about $44.35. It is an estimate from reported earnings, not a price target.
Is GCO overvalued or undervalued?
Against a Modified-Graham fair-value estimate, GCO currently appears undervalued relative to its SEC-grounded earnings power.
What is GENESCO INC's quality score?
GCO scores 67.74509803921568/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000018498, latest 10-Q filed 2026-06-11) · EODHD · as of 6/26/2026, 7:49:25 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-04-02
Ewoldsen Daniel E
Senior VP
Award7.68K
2026-04-02
Becker Scott E
SVP, Secretary & Gen Counsel
Award9.90K
2026-04-02
VAUGHN MIMI ECKEL
Board Chair, President & CEO
Award74.8K
2026-04-02
Gray Andrew
Senior VP
Award376.00
2026-04-02
Ewoldsen Daniel E
Senior VP
Tax1.53K @ $28.39$43.4K
2026-04-02
Gray Andrew
Senior VP
Tax2.14K @ $28.39$60.8K
2026-04-02
Desai Parag
SVP, Chief Strat & Dig Officer
Tax2.19K @ $28.39$62.1K
2026-04-02
Becker Scott E
SVP, Secretary & Gen Counsel
Tax1.95K @ $28.39$55.2K

Earnings history

beat/miss · move
2026-05-29Beat +3.3% est▲ +5.47%8-K ↗
2026-03-06Miss -11.1% est▲ +1.57%8-K ↗
2025-12-04Beat +9.5% est▼ -30.84%8-K ↗
2025-08-28—▼ -5.91%8-K ↗
2025-06-04—▼ -0.27%8-K ↗
2025-03-07—▼ -16.33%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Is Hollister Emerging as a Key Growth Driver for Abercrombie?Bullish
finance.yahoo.com· 2026-06-24
G-III Capitalizes on DTC Growth Through AI & Digital InnovationBullish
finance.yahoo.com· 2026-06-23
Stitch Fix Boosts Revenues Per Active Client Through PersonalizationBullish
finance.yahoo.com· 2026-06-23
Best Value Stocks to Buy for June 23rdBullish
finance.yahoo.com· 2026-06-23
Reflecting On Consumer Discretionary - Footwear Stocks’ Q1 Earnings: Deckers (NYSE:DECK)Bullish
finance.yahoo.com· 2026-06-22
A Look Back at Consumer Discretionary - Footwear Stocks’ Q1 Earnings: Nike (NYSE:NKE) Vs The Rest Of The PackBullish
finance.yahoo.com· 2026-06-19

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score68 vs 67
Revenue growth4.8% vs 7.1%
Net margin0.5% vs 10.5%
Return on equity2.3% vs 12.3%
P/E28.9 vs 25.5

News sentiment

EODHD · 24d
Bullish
+0.17
vs typical · 41 articles

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.